Dendritic cell therapy in combination with interferon-alpha
for the treatment of renal cell carcinoma meta-static.

Tatsugami K, Eto M, Harano M, Hamaguchi M, Miyamoto T, Morisaki T, Furue M, Akashi K, Naito S. Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Objectives: To Evaluate the safety and efficacy of dendritic cell (DC) therapy in combination with interferon-alpha (IFN-alpha) in patients with advanced renal cell carcinoma.

Methods: Patients Seven, with progressive disease following IFN-alpha and interleukin (IL) -2 treatment, Were Treated with monocyte-derived DC (Mo-DC) and IFN-alpha between February 2004 and September 2006. They Received Mo-DC once a week for 5 weeks and then everytime 2 weeks intradermally or intratumorally Either. IFN-alpha (5-6 million U) was Administered subcutaneously three times a week. Tumor size was evaluated by computed tomography scans before and after the 5th and 10th DC vaccination. A delayed-type hyper-sensitivity test was Performed after the 4th and 5th DC Administration for immuno-logical monitoring.

Results: Five patient experienced stable disease while the patient experienced progressive disease Remaining two following four months of vaccination. Patients in the six time to progression was prolonged in comparison with the previous cytokine treatment. Six Patients showed delayed-type hyper sensitivity after the 4th or 5th immunization. Three Patients Developed high fever following DC immunization. Treatment was associated with transient flu-like symptoms.

Conclusions: Our data Indicating That DC therapy combined with IFN-alpha is safe and HAS the potential for prolonging the time to progression in patient with advanced renal cell carcinoma.

PMID: 18564205 [PubMed - as supp song by publisher]